Heron Therapeutics Inc. (HRTX)
Heron Therapeutics Inc. (HRTX) Stock Price, Analysis & Data
| Bid | 0.3 |
| Market Cap | 64.72M |
| Revenue (ttm) | 151.18M |
| Net Income (ttm) | -34.05M |
| Beta | 1.67 |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.1 |
| P/B (ttm) | 11.00 |
| P/S (ttm) | 0.43 |
| Earnings Date | Nov 3, 2026 |
| Ask | 0.4 |
| Volume | 3,571,754 |
| Avg. Volume (20D) | 3,439,890 |
| Open | 0.32 |
| Previous Close | 0.32 |
| Day's Range | 0.31 - 0.36 |
| 52-Week Range | 0.30 - 1.58 |
| Analyst | Buy |
| Price Target | 2 (488.24%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HRTX
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release in...
Financial Performance
In 2025, Heron Therapeutics's revenue was 154.9M, an increase of 7.36% compared to the previous year's 144.28M. Earnings were -20.2M, an increase of 48.71%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for HRTX stock is "Buy". The 12-month stock price forecast is 2, which is upside of 488.24% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
